Novo Nordisk says trial of oral weight-loss drug shows significant result
COPENHAGEN (Reuters) - Novo Nordisk's trial of the oral version of its weight-loss drug semaglutide has shown statistically significant and superior weight loss when compared to a placebo, the drugmaker...








